How many insider trades does FilingIQ track for VNDA?

FilingIQ tracks 401 Form 4 insider transactions for VNDA (Vanda Pharmaceuticals Inc.), covering filings from Feb 9, 2015 onwards. 0 of those are dated within the last 90 days.

Are VNDA insiders net buyers or net sellers?

Across the full Form 4 history for VNDA, 36 transactions (9%) were open-market purchases and 168 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VNDA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is VNDA in?

Vanda Pharmaceuticals Inc. (VNDA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $359.38M.

VNDA insider trading

NasdaqGM Healthcare

Vanda Pharmaceuticals Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

401

Last 90 days

Buys / sells

9% / 42%

Market cap

$359.38M

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Company website: www.vandapharma.com

VNDA insider activity at a glance

FilingIQ tracks 401 insider transactions for VNDA in filings since Feb 9, 2015. The most recent transaction is dated Jun 4, 2026.

Across the full history, 36 open-market purchases and 168 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VNDA insider trades is 53.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VNDA trades on FilingIQ Raw filings on SEC EDGAR

Latest VNDA Form 4 filings

McGuire Daniel Patrick SVP, GC and Secretary

Moran Kevin Patrick SVP, CFO & Treasurer

S Mar 4, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for VNDA?: FilingIQ tracks 401 Form 4 insider transactions for VNDA (Vanda Pharmaceuticals Inc.), covering filings from Feb 9, 2015 onwards. 0 of those are dated within the last 90 days.
Are VNDA insiders net buyers or net sellers?: Across the full Form 4 history for VNDA, 36 transactions (9%) were open-market purchases and 168 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VNDA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is VNDA in?: Vanda Pharmaceuticals Inc. (VNDA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $359.38M.

Methodology & sources

Every VNDA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.